Read More

89bio Data Showed Pegozafermin Treatment Was Found To Be Effective In Reducing Triglycerides And Other Atherogenic Lipids In Patients With SHTG, Regardless Of Their Background Lipid-modifying Therapy

89bio, Inc. (Nasdaq: ETNB) today announced the presentation of additional data from the Phase 2 ENTRIGUE trial of pegozafermin in patients with severe hypertriglyceridemia (SHTG) at the American College of Cardiology's 72nd Annual Scientific Session & Expo Together with World Congress of Cardiology (ACC.23/WCC).

ETNB

Read More

Johnson & Johnson Unit Janssen Announced New STELARA Long-Term Data Support Its Established Safety Profile In Inflammatory Bowel Disease And Durable Efficacy In Ulcerative Colitis

he Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn's disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extensi

JNJ

Read More

Option Care Health On Wednesday Priced Secondary Offering of 13,000,000 Shares of Common Stock By Affiliate Of Walgreens Boots Alliance @$30.75/Share

Option Care Health, Inc. (NASDAQ: OPCH) announced that an affiliate of Walgreens Boots Alliance, Inc. (the "Selling Stockholder") has agreed to sell 13,000,000 shares of the Company's common stock at a price to the public of $30.75 per share in an underwritten secondary offering.

OPCH